241 related articles for article (PubMed ID: 30814855)
1. Exploration of the binding pocket of histone deacetylases: the design of potent and isoform-selective inhibitors.
Uba Aİ; Yelekçi K
Turk J Biol; 2017; 41(6):901-918. PubMed ID: 30814855
[TBL] [Abstract][Full Text] [Related]
2. Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay.
Uba AI; Yelekçi K
J Biomol Struct Dyn; 2018 Sep; 36(12):3231-3245. PubMed ID: 28938863
[TBL] [Abstract][Full Text] [Related]
3. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
[TBL] [Abstract][Full Text] [Related]
4. Energy-optimised pharmacophore approach to identify potential hotspots during inhibition of Class II HDAC isoforms.
Ganai SA; Shanmugam K; Mahadevan V
J Biomol Struct Dyn; 2015; 33(2):374-87. PubMed ID: 24460542
[TBL] [Abstract][Full Text] [Related]
5. The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods.
Curcio A; Rocca R; Alcaro S; Artese A
Pharmaceuticals (Basel); 2024 May; 17(5):. PubMed ID: 38794190
[TBL] [Abstract][Full Text] [Related]
6. Structure-based virtual screening for novel potential selective inhibitors of class IIa histone deacetylases for cancer treatment.
Elmezayen AD; Kemal Y
Comput Biol Chem; 2021 Jun; 92():107491. PubMed ID: 33930743
[TBL] [Abstract][Full Text] [Related]
7. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
[TBL] [Abstract][Full Text] [Related]
8. Pharmacophore-based virtual screening for identification of potential selective inhibitors of human histone deacetylase 6.
Uba AI; Yelekçi K
Comput Biol Chem; 2018 Dec; 77():318-330. PubMed ID: 30463049
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel class I and class IIb histone deacetylase inhibitor for Alzheimer's disease therapeutics.
Gupta R; Ambasta RK; Kumar P
Life Sci; 2020 Sep; 256():117912. PubMed ID: 32504755
[TBL] [Abstract][Full Text] [Related]
10. Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy.
Ganai SA
Curr Top Med Chem; 2016; 16(22):2441-52. PubMed ID: 26873193
[TBL] [Abstract][Full Text] [Related]
11. Energy based pharmacophore mapping of HDAC inhibitors against class I HDAC enzymes.
Kalyaanamoorthy S; Chen YP
Biochim Biophys Acta; 2013 Jan; 1834(1):317-28. PubMed ID: 23457710
[TBL] [Abstract][Full Text] [Related]
12. Pharmacophore-enabled virtual screening, molecular docking and molecular dynamics studies for identification of potent and selective histone deacetylase 8 inhibitors.
Kashyap K; Kakkar R
Comput Biol Med; 2020 Aug; 123():103850. PubMed ID: 32658783
[TBL] [Abstract][Full Text] [Related]
13. Virtual screening and experimental validation of novel histone deacetylase inhibitors.
Huang YX; Zhao J; Song QH; Zheng LH; Fan C; Liu TT; Bao YL; Sun LG; Zhang LB; Li YX
BMC Pharmacol Toxicol; 2016 Jul; 17(1):32. PubMed ID: 27443303
[TBL] [Abstract][Full Text] [Related]
14. Explorative study on isoform-selective histone deacetylase inhibitors.
Suzuki T
Chem Pharm Bull (Tokyo); 2009 Sep; 57(9):897-906. PubMed ID: 19721249
[TBL] [Abstract][Full Text] [Related]
15. Development and therapeutic impact of HDAC6-selective inhibitors.
Dallavalle S; Pisano C; Zunino F
Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
Cao F; Zwinderman MRH; van Merkerk R; Ettema PE; Quax WJ; Dekker FJ
Eur J Med Chem; 2019 Sep; 177():457-466. PubMed ID: 31181405
[TBL] [Abstract][Full Text] [Related]
17. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases.
Wang DF; Helquist P; Wiech NL; Wiest O
J Med Chem; 2005 Nov; 48(22):6936-47. PubMed ID: 16250652
[TBL] [Abstract][Full Text] [Related]
18. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
19. Optimization of Resveratrol Used as a Scaffold to Design Histone Deacetylase (HDAC-1 and HDAC-2) Inhibitors.
Urias BS; Pavan AR; Albuquerque GR; Prokopczyk IM; Alves TMF; de Melo TRF; Sartori GR; da Silva JHM; Chin CM; Santos JLD
Pharmaceuticals (Basel); 2022 Oct; 15(10):. PubMed ID: 36297372
[TBL] [Abstract][Full Text] [Related]
20. Exploring structural requirements of isoform selective histone deacetylase inhibitors: a comparative
Kashyap K; Kakkar R
J Biomol Struct Dyn; 2021 Feb; 39(2):502-517. PubMed ID: 31900046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
